ArticleFrontiers in cardiovascular medicine2025
Identification and validation of key genes associated with cell senescence in acute myocardial infarction.
Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Integrative systems biology identifies SIRT1 as a senescence-related theranostic target in atherosclerosis and poliumoside as a natural activator.Frontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Cellular senescence can cause heart failure. However, studies on diagnostic markers related to cellular senescence in acute myocardial infarction (AMI) have not been reported. Therefore, this study explores the mechanism of key genes related to cellular senescence in acute myocardial infarction (AMI) through a bioinformatics approach. Methods: AMI related datasets were obtained from gene expression omnibus (GEO) database, and 3,058 cellular senescence related genes (CSRGs) were extracted from Molecular Signatures Database (MSigDB). First, differentially expressed genes (DEGs) were screened by differential expression analysis,and then Weighted gene co-expression network analysis (WGCNA) was performed to obtained the key module. CSRGs, DEGs and genes in key module were intersected to acquire intersected genes, and candidate genes were also screened out by constructing a protein protein interaction (PPI) network.Afterwards, candidate genes were then subjected to a machine learning approach to identify key genes and enrichment analyses were performed on individual genes Finally, immuno-infiltrative analysis, competing-endogenous RNA (ceRNA) and drug-gene networks construction were conducted. Besides, the expression of key genes were validated by quantitative real-time polymerase chain reaction (qRT-PCR). Results: Screening for two key genes (ATP6V0B and DYNLL1) from 914 DEGs, and they were involved in functional pathways such as 'mast cell activation', 'cytosolic ribosome'. Thereafter, we found infiltration of neutrophils, CD4 T cells memory resting and T cells gamma delta was notably different between AMI and control samples. Pearson correlation analysis suggested that the neutrophils had highest positive correlation with ATP6V0B (Cor = 0.7), while had highest negative correlation with DYNLL1 (Cor = -0.6). The ceRNA network had one mRNA (DYNLL1), one miRNA (hsa-miR-330-5p) and four circRNAs. Eventually, drug-ATP6V0B network had 74 nodes and 73 edges, drug-DYNLL1 network had 119 nodes and 118 edges. qRT-PCR suggested that the expression trend of DYNLL1 was consistent with the result of bioinformatic analysis. Notably, DYNLL1 was significantly down-regulated in the case group. Conclusion: Identified and validated DYNLL1 as a key gene related to cellular senescence in AMI, which is of great significance for the diagnosis and molecular targeted therapy of AMI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.